Input 2021.02.08 15:08 | Revision 2021.02.08 16:25
Modena “reduced neutralizing antibody production by one-sixth…prevention is possible”
Janssen-Novabax effect’tuk’… Pfizer needs additional verification–
–
According to a foreign press on the 8th, it was difficult to prevent infection with the AstraZeneca vaccine against the South African mutant virus, which is currently at an increased risk of spreading worldwide. The rest of the vaccines have reported more positive results, but their effectiveness is greatly reduced or further validation is needed.
According to Reuters on the day, health authorities in South Africa, the source of the South African mutation, decided to withhold the domestic use of the AstraZeneca vaccine. In the future, it will be decided whether to use it after consulting experts.
According to the Wall Street Journal (WSJ) that day, a joint research team at Oxford University in the UK and the University of Bitbadersland in South Africa, which jointly developed the AstraZeneca vaccine, recently tested the effect of mutations in South Africa on 2026 people. , It was not possible to prevent the mild and moderate expression by the mutant virus.”
Professor Nam Jae-hwan of the Department of Medical Life Science at the Catholic University also attended a briefing by the Korea Centers for Disease Control and Prevention and said, “The price of neutralizing antibodies has fallen from 60% to 20%.” The existing effectiveness of this vaccine was reported at 66%. The British and South African researchers hope that infection can reduce the risk of severe development and death, but no definitive research results have yet been released.
The health authorities warned the day before that “overseas, the virus is spreading more and more rapidly and is becoming a dominant species.” AstraZeneca announced that it will develop and produce next-generation vaccines that can more effectively prevent mutant viruses by this fall. For this reason, a total of 10 million people will enter the country from this month, and this vaccine, which will be used in earnest from the second quarter, is expected to have limitations in preventing the South African mutant from becoming the dominant species.
–
–
Modena said, “This level of neutralizing antibody transfer is above the level that can protect the inoculator from the South African mutant virus,” and “We plan to start a clinical trial soon to increase the efficacy of Boostershot (2nd vaccination) to increase the preventive effect.” Said.
The Pfizer vaccine, which has previously reported 95% of the preventive effect, was also confirmed to be effective against mutations in South Africa. Antibodies made in the vaccinator’s body were administered to the cells and they were not infected with the mutant virus. “It means that the key mutations in the South African variant virus cannot overcome the immune response induced by our vaccine,” Pfizer said. However, since it is still an experimental result obtained at the cellular level in a laboratory, it is still uncertain until further verification through clinical trials.
Modena and Pfizer vaccines are evaluated as relatively easy to respond to mutations because their main component is’messenger ribonucleic acid (mRNA)’, which is the’blueprint’ required for the body to make neutralizing antibodies. This is because you only need to draw a new blueprint according to the virus mutation. For the same reason, the current supply was completed in 10 months, which is faster than the existing vaccine. However, there is a disadvantage in that supply is insufficient worldwide.
–
–
NovaVax vaccine also failed to maintain 89% of the existing mutations in South Africa. Also, in clinical trials for South African patients, it showed 49% effect on HIV carriers and 60% on non-carriers.
Janssen and NovaVax vaccines are expected to contribute to the formation of population immunity to some extent, even if the South African mutation becomes the dominant species, it still exceeds 50%, the prevention effect evaluation standard set by the World Health Organization (WHO) and Korean health authorities. However, the Janssen vaccine is supplied only to 6 million people, the smallest amount of vaccines introduced in Korea, and the supply of NovaVax vaccine has not been completed yet, so the supply is uncertain.
The number of domestic mutant virus confirmed cases counted up to the previous day was 51, of which 9 were confirmed mutant in South Africa. It is known that the South African mutant virus has 1.5 times higher transmission power than before and has a higher risk of re-infection by reducing the lifespan of neutralizing antibodies. It is reported that the efficacy against the British mutant virus, another variant, is maintained to some extent in all five vaccines.
–
– .
